Dividends Inside 
Imac Holdings Inc.
BACK
$0.04 (- $0.01 - 13.04%)
Last updated: 2026-05-20 22:42 UTC
Imac Holdings Inc. trades under ticker BACK on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US44967K3023, CUSIP 44967K302.
About the Company
IMAC Holdings, Inc. is a clinical research and commercialization company focused on combining life science advancements with traditional medical care across oncology, neurological, and orthopedic specialties. Operating through its subsidiary Ignite Proteomics LLC, the company provides proteomic products and precision medicine services utilizing a patented phosphoprotein and protein biomarker platform. Its reverse phase protein array (RPPA) technology quantifies protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. IMAC Regeneration Centers deliver natural, non-opioid solutions for pain management, addressing demand for conservative treatments in an aging population. The company's laboratory developed tests are utilized by oncologists across the United States to assist in targeted treatment planning for patients with advanced breast cancer. Additionally, IMAC conducts clinical trials for investigational compounds, including umbilical cord-derived allogenic mesenchymal stem cells for neurological conditions. Headquartered in Franklin, Tennessee, IMAC Holdings serves as a bridge between precision diagnostics and personalized medical care in specialized healthcare markets.
Price History
Latest News for BACK
Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers
The First Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-Tumor Study Golden, CO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (OTCQB: BACK), today announced that it has entered into a research collaboration with Inova Health to apply Ignite’s Reverse Phase Protein Array (RPPA) technology to tumor samples from patients, primarily with late-stage gastrointestinal cancers. Th
IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery
Project will leverage Ignite Proteomics’ reverse-phase protein array (RPPA) platform to profile tumor-immune signaling in breast-cancer samples Golden, CO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (OTCQB: BACK), today announced a one-year research collaboration with Vanderbilt University Medical Center (VUMC) to characterize protein-signaling pathways that help breast-tumor cells evade the immune system. Under the agreement, VUMC will provide d
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company’s new Chief Financial Officer (CFO). He succeeds Alexande